1 Oct 2026, 10:26 amInsider Trading / SAST
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Aspira Pathlab & Diagnostics Ltd operates in Healthcare Service Provider within the Healthcare sector.
1,304 historical price candles were omitted because the exchange source has not been verified.
Structured signal from quality, growth, valuation and momentum.
₹ crore, by fiscal year
% of revenue, by fiscal year
Comparable companies from the narrowest available industry classification.
Reported profit and loss, balance sheet, cash flow and growth history.
Annual operating, return, leverage and working-capital ratios.
Current futures and options contracts with compact option-chain pages.
Mutual-fund schemes that disclosed a holding in the company.
Annual reports, exchange filings, offer documents, ratings and earnings-call material.
Upcoming dates and the company’s corporate-action history.
Latest exchange announcements, filings and downloadable documents.
Consolidated figures
| Ratio | Mar 2024 | Mar 2025 |
|---|---|---|
| Margins | ||
| Gross margin % | 80.2% | 83.2% |
| EBITDA margin % | -9% | 16% |
| EBIT margin % | -20.7% | 9.2% |
| PAT margin % | -20.2% | 9.2% |
| Working capital | ||
| Receivable days | 62 | 39 |
| Inventory days | 63 | 50 |
| Payable days | — | 73 |
| NWC days | — | 16 |
| Leverage | ||
| Current ratio | 2.11 | 2.26 |
| Debt to EBITDA | — | 0.34 |
| Debt to equity | 0.11 | 0.1 |
| Interest coverage | -6.2 | 6.9 |
| Asset turnover | 0.9 | 1.26 |
| Return ratios | ||
| Return on assets % | -18.2% | 11.6% |
| Return on capital employed % | -18.3% | 17.5% |
| Return on equity % | -26.3% | 16.6% |
Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.
Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.
No scheme among the 32 fund houses on record reported a position in Aspira Pathlab & Diagnostics Ltd. Portfolios are published monthly by each AMC; coverage is still partial.
| Holder (%) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18.9% | 18.9% | 18.72% | 18.72% | 18.55% | 18.55% | 18.39% | 18.39% | 18.39% | 18.39% | 18.39% | 46.58% | |
| FII | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DII | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 81.1% | 81.1% | 81.28% | 81.28% | 81.45% | 81.45% | 81.61% | 81.61% | 81.61% | 81.61% | 81.61% | 53.42% | |
| No. of shareholders | — | — | — | — | — | — | — | — | 1,755 | 1,784 | 1,769 | 1,620 |
Promoter holding up 27.68 percentage points since Sep 2023.
| Date | Client | Type | Venue | Side | Quantity | Price | Value |
|---|---|---|---|---|---|---|---|
| 21 Jul 2026 | INVESTERIA FINANCIAL SERVICES PRIVATE LIMITED | Bulk | BSE | Sell | 1,03,732 | ₹88.67 | ₹0.92 Cr |
| 21 Jul 2026 | VINOD CHANDULAL MAV | Bulk | BSE | Buy | 53,900 | ₹88.50 | ₹0.48 Cr |
| 17 Jul 2026 | INVESTERIA FINANCIAL SERVICES PRIVATE LIMITED | Bulk | BSE | Sell | 1,00,000 | ₹85.00 | ₹0.85 Cr |
| 9 Oct 2025 | DIVYA KANDA | Bulk | BSE | Buy | 52,130 | ₹59.56 | ₹0.31 Cr |
| 9 Oct 2025 | DIVYA KANDA | Bulk | BSE | Sell | 14,721 | ₹61.97 | ₹0.09 Cr |
| 6 Oct 2025 | DEVJI DEYAT NANDA | Bulk | BSE | Sell | 90,000 | ₹75.26 | ₹0.68 Cr |
| 25 Aug 2025 | ADEQUATE REAL TRADE LLP | Bulk | BSE | Buy | 72,000 | ₹58.99 | ₹0.42 Cr |
| 2 Jul 2024 | SOCRADAMUS CAPITAL PRIVATE LIMITED . | Bulk | BSE | Sell | 1,25,000 | ₹28.85 | ₹0.36 Cr |
| 2 Jul 2024 | RAJESH PREMJI BHANUSHALI | Bulk | BSE | Buy | 68,682 | ₹28.34 | ₹0.19 Cr |
| 28 Jun 2024 | GLORIOUS HOLDINGS PVT LTD | Bulk | BSE | Sell | 75,000 | ₹30.00 | ₹0.23 Cr |
Current officeholders as filed with BSE. A person holding two offices is listed once per office.
Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.
| Company | Mkt Cap | EV | Revenue | EBITDA | OPM | PAT | NPM | ROCE | ROE | WC Days |
|---|---|---|---|---|---|---|---|---|---|---|
| Dr. Lal Path Labs Ltd.LALPATHLABLALPATHLAB | ₹33,605 Cr | ₹33,605 Cr | ₹2,891 Cr | ₹838 Cr | 28.3% | ₹542 Cr | 18.5% | 28.8% | 21.6% | -79 |
| Vijaya Diagnostic Centre LimitedVIJAYAVIJAYA | ₹14,694 Cr | ₹14,694 Cr | ₹857 Cr | ₹362 Cr | 41.4% | ₹187 Cr | 21.3% | 21.3% | 19.7% | -117 |
| Metropolis Healthcare LimitedMETROPOLISMETROPOLIS | ₹11,151 Cr | ₹11,169 Cr | ₹1,710 Cr | ₹422 Cr | 24.4% | ₹202 Cr | 11.6% | 17.3% | 13.4% | -57 |
| Thyrocare Technologies LimitedTHYROCARETHYROCARE | ₹8,495 Cr | ₹8,495 Cr | ₹876 Cr | ₹282 Cr | 31.6% | ₹176 Cr | 19.6% | 36.5% | 28.8% | 4 |
| Nephrocare Health Services LimitedNEPHROPLUSNEPHROPLUS | ₹6,509 Cr | ₹6,589 Cr | ₹999 Cr | ₹227 Cr | 22.7% | ₹77 Cr | 7.7% | 17.1% | 9.1% | -61 |
| Suraksha Diagnostic LimitedSURAKSHASURAKSHA | ₹1,824 Cr | ₹1,826 Cr | ₹325 Cr | ₹102 Cr | 30.7% | ₹36 Cr | 10.1% | 16.8% | 14.1% | -101 |
| Krsnaa Diagnostics LimitedKRSNAAKRSNAA | ₹1,798 Cr | ₹2,332 Cr | ₹815 Cr | ₹218 Cr | 27.4% | ₹97 Cr | 13.1% | 13.1% | 10.9% | 65 |
| 3b Blackbio Dx Limited3BBLACKBIO3BBLACKBIO | ₹1,416 Cr | ₹1,417 Cr | ₹96 Cr | ₹50 Cr | 52% | ₹163 Cr | 49.4% | 25.3% | 19.4% | 235 |
| One Global Service Provider LtdONEGLOBALONEGLOBAL | ₹1,025 Cr | ₹1,025 Cr | ₹6 Cr | ₹1 Cr | 22.2% | ₹1 Cr | 17.3% | 17.6% | 19.5% | — |
| Health X Platform LimitedHEALTHXHEALTHX | ₹868 Cr | ₹890 Cr | ₹1,468 Cr | ₹-67 Cr | -4% | ₹-20 Cr | -0.1% | — | 0.2% | — |
| Gaudium Ivf And Women Health LimitedGAUDIUMIVFGAUDIUMIVF | ₹797 Cr | ₹820 Cr | ₹104 Cr | ₹38 Cr | 36.1% | ₹24 Cr | 23.4% | 23.1% | 16.1% | 92 |
| Aspira Pathlab & Diagnostics LtdASPIRAASPIRA | ₹135 Cr | ₹136 Cr | ₹22 Cr | ₹4 Cr | 16% | ₹2 Cr | 9.2% | 17.5% | 18.1% | 16 |
Documents link to external sources (exchange filings, company investor pages).
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Announcement Under Regulation 30_Constitution Of Right Issue Committee
Announcement under Regulation 30 (LODR)-Raising of Funds
Board Meeting Outcome for Outcome Of Board Meeting Held On 12Th September 2026
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Board Meeting Intimation for To Consider Approve The Proposal For Raising Funds Through The Issuance Of Equity Shares, Warrants Convertible Into Equity Shares, Or Other Permitted Instruments By Way Of Preferential Issue, Private Placement, Rights Issue Or Any Combination.
| Date | Category | Subject | Filing |
|---|---|---|---|
| 1 Oct 2026, 10:26 am | Insider Trading / SAST Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 | |
| 28 Sept 2026, 10:26 am | Insider Trading / SAST Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 | |
| 16 Sept 2026, 6:11 pm | Insider Trading / SAST Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 | |
| 12 Sept 2026, 4:57 pm | Company Update General | Announcement Under Regulation 30_Constitution Of Right Issue Committee | |
| 12 Sept 2026, 4:52 pm | Company Update Raising of Funds | Announcement under Regulation 30 (LODR)-Raising of Funds | |
| 12 Sept 2026, 4:48 pm | Board Meeting Outcome of Board Meeting | Board Meeting Outcome for Outcome Of Board Meeting Held On 12Th September 2026 | |
| 12 Sept 2026, 1:20 pm | Insider Trading / SAST Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 | |
| 7 Sept 2026, 1:45 pm | Board Meeting | Board Meeting Intimation for To Consider Approve The Proposal For Raising Funds Through The Issuance Of Equity Shares, Warrants Convertible Into Equity Shares, Or Other Permitted Instruments By Way Of Preferential Issue, Private Placement, Rights Issue Or Any Combination. |
Consolidated figures · ₹ crore
| ₹ Cr | Mar 2024 | Mar 2025 |
|---|---|---|
| 13 | 22 | |
| COGS | 3 | 4 |
| Gross profit | 11 | 18 |
| 12 | 15 | |
| -1 | 4 | |
| OPM % | -9% | 16% |
| Depreciation | 2 | 1 |
| Interest | 0 | 0 |
| 0 | 0 | |
| Profit before tax | -3 | 2 |
| Tax | — | 0 |
| PAT | -3 | 2 |
| PAT margin % | -20.2% | 9.2% |
| EPS (₹) | -2.6 | 2 |
| EPS adjusted (₹) | -2.6 | 2 |
| Annual report | Annual report for Mar 2024 | Annual report for Mar 2025 |
| ₹ Cr | Mar 2024 | Mar 2025 |
|---|---|---|
| Equity capital | 10 | 10 |
| Reserves | -0 | 2 |
| Minority interest | — | 0 |
| 1 | 1 | |
| 3 | 4 | |
| Total equity & liabilities | 15 | 17 |
| 5 | 7 | |
| CWIP | — | — |
| Investments | 0 | 0 |
| 9 | 11 | |
| Total assets | 15 | 17 |
| ₹ Cr | Mar 2024 | Mar 2025 |
|---|---|---|
| 1 | 2 | |
| 0 | 0 | |
| -1 | -1 | |
| Net cash flow | 0 | 1 |
| Free cash flow | 1 | 1 |
| CFO / Operating profit % | — | 52% |